Used in research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK1, CDK2, CDK4, and CDK7. It has shown promise in preclinical studies for cancer treatment due to its ability to block cell cycle progression and inhibit tumor cell proliferation. Demonstrates activity against various cancer cell lines, including those resistant to other chemotherapeutic agents. Investigated for potential use in combination therapies to enhance the efficacy of existing anticancer drugs. Not approved for clinical use and remains primarily a tool compound in oncology research.